13 completed, 4 terminated, 2 withdrawn. 11 Phase 1, 8 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 7, Terminated 2, Withdrawn 2 |
| Phase 2 | 8 | Completed 6, Terminated 1, Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow linifanib: new trials by email Literature Review of linifanib trials Research Report on linifanib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis Linifanib, BIBW2992, Axitinib - Endometriosis, Endometriosis Ovary | Phase 1 / Phase 2 | Withdrawn | BioGene Pharmaceutical Ltd. | 2021-10-10 | 2021-10-29 | |
| A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors linifanib - Advanced or Metastatic Solid Tumors | Phase 1 | Terminated | Abbott | 14 | 2011-10-01 | 2012-08-28 |
| A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors. [14C]linifanib, ABT-869, linifanib - Advanced Solid Tumors | Phase 1 | Terminated | Abbott | 3 | 2011-08-01 | 2012-09-21 |
| Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer linifanib - Recurrent Colon Cancer, Recurrent Rectal Cancer | Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 30 | 2011-06-01 | 2014-08-26 |
| An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors linifanib - Advanced Solid Tumors | Phase 1 | Completed | AbbVie | 35 | 2011-06-01 | 2017-11-21 |
| Effect of Rifampin on the Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors Linifanib, Rifampin - Advanced Solid Tumors | Phase 1 | Completed | Abbott | 14 | 2011-05-01 | 2011-11-02 |
| To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib. linifanib - Advanced Solid Tumors | Phase 1 | Completed | Abbott | 13 | 2011-05-01 | 2012-03-23 |
| A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC) Linifanib, Carboplatin, Paclitaxel - Non-Small Cell Lung Cancer | Phase 1 | Completed | AbbVie | 12 | 2010-09-01 | 2017-11-21 |
| A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869) ABT-869, ketoconazole - Solid Tumors | Phase 1 | Completed | Abbott | 12 | 2010-05-01 | 2011-07-26 |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) ABT-869, Sorafenib - Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent | Phase 3 | Terminated | Abbott | 1035 | 2010-01-01 | 2012-09-10 |
| Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869 ABT-869 - Advanced Solid Tumors | Phase 1 | Completed | AbbVie (prior sponsor, Abbott) | 34 | 2009-02-01 | 2017-11-21 |
| Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer ABT-869, bevacizumab, oxaliplatin - Advanced Colorectal Cancer, Adenocarcinoma of the Colon | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 159 | 2008-10-01 | 2013-05-15 |
| A Phase 1 Study of ABT-869 in Subjects With Solid Tumors ABT-869 - Solid Tumor | Phase 1 | Completed | AbbVie | 18 | 2008-09-01 | 2017-11-21 |
| Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors ABT-869, Tarceva - Solid Tumors | Phase 1 | Withdrawn | Abbott | 2008-09-01 | 2011-01-19 | |
| Phase 2 Study of ABT-869 in Combination With Paclitaxel Versus Paclitaxel Alone to Treat Metastatic Breast Cancer ABT-869, paclitaxel, Placebo for ABT-869 - Metastatic Breast Cancer | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 10 | 2008-07-01 | 2013-01-29 |
| Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) ABT-869, Placebo for ABT-869, Carboplatin - Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 145 | 2008-06-01 | 2013-04-29 |
| Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) ABT-869 - Advanced Hepatocellular Carcinoma | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 44 | 2007-09-01 | 2013-01-04 |
| Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) ABT-869 .25 mg/kg, ABT-869 0.10 mg/kg - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 140 | 2007-08-01 | 2013-04-05 |
| Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib ABT-869 - Advanced Renal Cell Carcinoma | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 53 | 2007-06-01 | 2013-01-04 |
Carcinoma, Non-Small-Cell Lung (3) · Colonic Neoplasms (2) · Rectal Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma (1) · Carcinoma, Hepatocellular (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endometriosis (1) · Liver Diseases (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
AbbVie (prior sponsor, Abbott) (7) · Abbott (7) · AbbVie (3) · BioGene Pharmaceutical Ltd. (1) · Vanderbilt-Ingram Cancer Center (1)
United States (13) · Canada (5) · Singapore (4) · Australia (3) · Czechia (3) · Russia (3) · Taiwan (3) · Belgium (2) · Brazil (2) · France (2) · Greece (2) · Mexico (2) · New Zealand (2) · Romania (2) · South Korea (2)
Mark D. McKee, MD (5) · Justin Ricker, MD (4) · Justin L. Ricker, MD (3) · Susumu Matsuki, BS (2) · Jordan Berlin, MD (1) · Mark D McKee, MD (1)
PMID 21597387, PMID 22078932, PMID 22382879, PMID 24241212, PMID 24807459, PMID 24810181, PMID 25488963, PMID 25559798, PMID 34052255
2009 (1)